Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)
June 17, 2021 11:21 AM EDTUpdated 11:48 AM
Coronavirus

'No rea­son to slow down any­thing here': Cure­Vac plans to march on with Covid-19 vac­cine af­ter piv­otal fail­ure

Nicole DeFeudis

Editor

The day af­ter Cure­Vac re­vealed its mR­NA vac­cine failed a piv­otal tri­al, crush­ing the com­pa­ny’s stock, a group of an­a­lysts tuned in­to the com­pa­ny call …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times